Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Therapie|June 16, 2022
Skin cancers under Janus kinase inhibitors: A World Health Organization drug safety database analysisCédric Jalles, Marion Lepelley, Stéphane Mouret, et al.
La Tunisie Medicale|December 30, 2006
[Norwegian scabies, a rare diagnosis in Tunisia]Amel Mebazaa, Bouraoui Bedday, Sabiha Trabelsi, et al.
European Journal of Dermatology : EJD|March 20, 2025
Home anti-PD1 immunotherapy for melanoma: results of a patient and nursing satisfaction surveyThu Thao Truong, Marie Lapassat, Aude Belbezier, et al.
La Tunisie Medicale|February 8, 2008
[Porokeratosis. A study about 6 cases]Sabiha Trabelsi, Talel Badri, Mourad Mokni, et al.
Oncoimmunology|April 22, 2020
An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trialJulie Charles, Laurence Chaperot, Dalil Hannani, et al.
Annals of the Rheumatic Diseases|July 5, 2022
Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case-control studyLéo Plaçais, Stéphane Dalle, Olivier Dereure, et al.
Journal for Immunotherapy of Cancer|March 12, 2024
High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinomaDanny Rischin, Brett G M Hughes, Nicole Basset-Séguin, et al.
European Journal of Cancer (Oxford, England : 1990)|March 10, 2026
Cemiplimab versus historical systemic treatments for locally advanced or metastatic cutaneous squamous cell carcinomas: Results from the French study TOSCACaroline Robert, Emilie Gérard, Emilie Lanoy, et al.
Journal of Oncology|January 12, 2019
Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal MelanomaClaire Mignard, Aurélie Deschamps Huvier, André Gillibert, et al.
Journal of the American Academy of Dermatology|September 8, 2024
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6Brett G M Hughes, Alexander Guminski, Samantha Bowyer, et al.
Pageof 1